reteplase is a potent thrombolytic agent which is widely used in the management of acute myocardial infarction and stroke. it belongs to the third generation of the thrombolytic drugs and has been derived from native human tissue plasminogen activator by removing three domains of it and keeping the kringle 2 and serine protease domains. however, the high cost of this drug, has limited the appli...

aggregation of pharmaceutical proteins reduces the efficiency and increases the cost of production. it can also lead to the reduced efficacy of drug or cause side effects on the patient’s body. investigating how to create them plays an important role to find agents that prevents the aggregation. this study was allocated for understanding the mechanism of formation of the reteplase protein using...

AIM The study aim is to evaluate the cost-effectiveness of thrombolytic treatment in acute MI comparing with anticoagulants therapy and between each other thrombolytic (SK, r-Pa). MATERIAL AND METHODS We used a prospective registry of all patients admitted for acute myocardial infarction in intensive care units in Tirana. The average drugs cost was calculated for the hospitalization period in...

We would like to comment on the recent article entitled “Stuck aortic valve treated by reteplase in a Bentall patient.” published in Anatol J Cardiol 2015; 15: 339-40 by Tanyeli et al. (1), in which the use of reteplase in a patient with a stuck aortic mechanical valve is reported. We believe there are some major drawbacks to be addressed regarding the diagnostic algorithm and the treatment of ...

Correspondence to: Dr Steen Dalby Kristensen, Skejby Hospital, DK-8200 Aarhus N, Denmark; [email protected] _________________________ T he treatment strategy for acute myocardial infarction (MI) with ST elevation or newly developed left bundle branch block has been focusing on immediate opening of the infarct related coronary artery. This is because the prognosis for the patient is dependent u...